New drug combo targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-stage study tests a new drug called TTX-080, which blocks a protein that helps cancers hide from the immune system. It is given alone or with other cancer drugs to people with advanced solid tumors (like colorectal cancer) that have not responded to standard therapies.…
Phase: PHASE1 • Sponsor: Tizona Therapeutics, Inc • Aim: Disease control
Last updated May 11, 2026 20:53 UTC